Rotavirus infections - Pipeline Insight, 2024

This “Rotavirus Infections - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Rotavirus Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Rotavirus Infections Understanding

Rotavirus Infections: Overview

Rotaviruses are non-enveloped double-stranded RNA (ds RNA) viruses that have a complex architecture of three concentric capsids that surround a genome of 11 segments of ds RNA. Rotavirus Infections are a leading cause of severe, dehydrating gastroenteritis in children < 5 years of age. Rotavirus is the most common cause of inflammation of the stomach and intestines (gastroenteritis), leading to severe diarrhea in infants and children throughout the world. There are different strains of rotavirus, and multiple infections by different strains may occur. Symptoms of rotavirus tend to be most prominent in children. The most common symptom of rotavirus is severe diarrhea. Children can also experience: vomiting, severe fatigue, a high fever, irritability, dehydration, and abdominal pain. In terms of treatment, the goal is to stay hydrated and comfortable while the virus works its way out of the system. There aren’t any medications or treatments that will make the rotavirus go away. This includes antiviral medications, over-the-counter antidiarrheal drugs,andantibiotics.

Rotavirus Infections - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rotavirus Infections pipeline landscape is provided which includes the disease overview and Rotavirus Infections treatment guidelines. The assessment part of the report embraces, in depth Rotavirus Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rotavirus Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Rotavirus Infections R&D. The therapies under development are focused on novel approaches to treat/improve Rotavirus Infections.

Rotavirus Infections Emerging Drugs Chapters

This segment of the Rotavirus Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rotavirus Infections Emerging Drugs

P2-VP8: PATH/ SK BiosciencesA next-generation, trivalent rotavirus P2-VP8 subunit recombinant vaccine, is being developed by PATH and SK Bioscience (a subsidiary of SK Chemicals), for the prevention of Rotavirus Infections. Clinical development is underway in US, South Africa and Zambia.

HSRV: Hilleman Laboratories Hilleman Labs new Rotavirus vaccine is a lyophilized heat stable rotavirus vaccine comprising of five live attenuated reassortant rotaviruses similar to RotaTeq®. The new heat stable rotavirus vaccine (HSRV) formulation offers a stability profile of 9 months at 45 °C and 12 months at 37 °C. HSRV was found to be generally well-tolerated in both adults and infants and immunogenic in infants in phase II clinicaltrials.

Rotavirus Infections: Therapeutic Assessment

This segment of the report provides insights about the different Rotavirus Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Rotavirus Infections

There are approx. 5+ key companies which are developing the therapies for Rotavirus Infections. The companies which have their Rotavirus Infections drug candidates in the most advanced stage, i.e. Phase III include, PATH/SK Biosciences.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Rotavirus Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rotavirus Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Rotavirus Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rotavirus Infections drugs.

Rotavirus Infections Report Insights

• Rotavirus Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Rotavirus Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Rotavirus Infections drugs?
• How many Rotavirus Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rotavirus Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rotavirus Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rotavirus Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.